SCHEMBL3640258

SCHEMBL3640258

COC(=O)C1=CC=CCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.46
CHRM3 P20309 2/20 0.42
LMNA P02545 3/20 0.41
CHRM2 P08172 1/20 0.41
CHRM4 P08173 1/20 0.41
CHRM5 P08912 1/20 0.41
THRB P10828 1/20 0.41
CHRM1 P11229 1/20 0.41
BLM P54132 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
TSHR P16473 2/20 0.33
CRHBP P24387 1/20 0.33
CRHR2 Q13324 1/20 0.33
CA1 P00915 4/20 0.32
CA2 P00918 4/20 0.32
CA12 O43570 4/20 0.32
CA9 Q16790 4/20 0.32
CA7 P43166 3/20 0.32
CA14 Q9ULX7 3/20 0.32
TDP1 Q9NUW8 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11797106 0.85 PTPN1 (0.39) PTPN1CHRM3LMNACHRM2CHRM4
SCHEMBL11797115 0.85 PTPN1 (0.39) PTPN1CHRM3LMNACHRM2CHRM4
SCHEMBL11797110 0.85 PTPN1 (0.39) PTPN1CHRM3LMNACHRM2CHRM4
SCHEMBL8947531 0.81
SCHEMBL18967982 0.81 PTPN1 (0.32) PTPN1
SCHEMBL6959856 0.80 PTPN1 (0.30) PTPN1
SCHEMBL24174146 0.79 PTPN1 (0.31) PTPN1CA1CA2CA12CA9
SCHEMBL5187673 0.79 TSHR (0.40) LMNATSHRCA1CA2CA12
SCHEMBL6967567 0.79 PTPN1 (0.31) PTPN1
SCHEMBL7632368 0.79 CHRM3 (0.40) PTPN1CHRM3LMNACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1569965-B1 METHOD FOR RADICAL POLYMERISATION IN THE PRESENCE OF A CHAIN TRANSFER AGENT BASF AG (DE) 2007-07-11 EP claimed
US-7196150-B2 Method for radical polymerisation in the presence of a chain transfer agent BASF AKTIENGESELLSCHAFT (DE) 2007-03-27 US claimed
US-20060058478-A1 Method for radical polymerisation in the presence of a chain transfer agent BASF AKTIENGESELLSCHAFT (DE) 2006-03-16 US claimed
EP-2618215-A1 Method for producing a lithographic printing plate Fujifilm Corporation (JP) 2013-07-24 EP disclosed
EP-2495245-A2 GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION FOB Synthesis, Inc. (US) 2012-09-05 EP disclosed
US-20100075945-A1 GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION CHOI WOO-BAEG 2010-03-25 US disclosed
US-7632828-B2 Gram-positive carbapenem antibacterials and processes for their preparation FOB SYNTHESIS, INC. (US) 2009-12-15 US disclosed
EP-1765821-A4 GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION FOB SYNTHESIS INC (US) 2009-05-20 EP disclosed
WO-2008156656-A2 METHOD FOR MAKING BIARYL COMPOUNDS, COMPOUNDS MADE BY THE METHOD, AND METHOD FOR THEIR USE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 2008-12-24 WO disclosed
WO-2008156656-A2 METHOD FOR MAKING BIARYL COMPOUNDS, COMPOUNDS MADE BY THE METHOD, AND METHOD FOR THEIR USE STATE OF OREGON ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) 2008-12-24 WO disclosed
EP-1795344-A1 Lithographic printing plate precursor and lithographic printing method FUJIFILM Corporation (JP) 2007-06-13 EP disclosed
US-20060074070-A1 Gram-positive carbapenem antibacterials and processes for their preparation FOB SYNTHESIS, INC. 2006-04-06 US disclosed
WO-2005123069-A2 GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION FOB SYNTHESIS, INC. (US) 2005-12-29 WO disclosed
EP-0609289-B1 IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME UPJOHN CO (US) 1996-07-17 EP disclosed
EP-0681582-A1 PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF PHARMACIA & UPJOHN COMPANY (US) 1995-11-15 EP disclosed
US-5442062-A Treating hypertension, congestive heart failure THE UPJOHN COMPANY (US) 1995-08-15 US disclosed
EP-0609289-A1 IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. UPJOHN CO (US) 1994-08-10 EP disclosed
WO-1994017069-A1 PYRAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF THE UPJOHN COMPANY (US) 1994-08-04 WO disclosed
EP-0540209-A1 Imidazole derivatives and pharmaceutical compositions containing the same THE UPJOHN COMPANY (US) 1993-05-05 EP disclosed
WO-1993008193-A1 IMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME THE UPJOHN COMPANY (US) 1993-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074070-A1 Gram-positive carbapenem antibacterials and processes for their preparation MGAM, GSK3B, GSK3A PTPN1 2049/4885CHRM3 3667/4885LMNA 1346/4885
US-20100075945-A1 GRAM-POSITIVE CARBAPENEM ANTIBACTERIALS AND PROCESSES FOR THEIR PREPARATION MGAM, GSK3B, GSK3A PTPN1 2049/4885CHRM3 3667/4885LMNA 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.